NZ609474A - Fviii peptides for immune tolerance induction and immunodiagnostics - Google Patents
Fviii peptides for immune tolerance induction and immunodiagnosticsInfo
- Publication number
- NZ609474A NZ609474A NZ609474A NZ60947411A NZ609474A NZ 609474 A NZ609474 A NZ 609474A NZ 609474 A NZ609474 A NZ 609474A NZ 60947411 A NZ60947411 A NZ 60947411A NZ 609474 A NZ609474 A NZ 609474A
- Authority
- NZ
- New Zealand
- Prior art keywords
- immune tolerance
- immunodiagnostics
- tolerance induction
- acid sequence
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ703514A NZ703514A (en) | 2010-10-27 | 2011-10-27 | Fviii peptides for immune tolerance induction and immunodiagnostics |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40740210P | 2010-10-27 | 2010-10-27 | |
| US201161467894P | 2011-03-25 | 2011-03-25 | |
| US201161502476P | 2011-06-29 | 2011-06-29 | |
| PCT/US2011/058165 WO2012058480A1 (en) | 2010-10-27 | 2011-10-27 | Fviii peptides for immune tolerance induction and immunodiagnostics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ609474A true NZ609474A (en) | 2015-06-26 |
Family
ID=45349271
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ609474A NZ609474A (en) | 2010-10-27 | 2011-10-27 | Fviii peptides for immune tolerance induction and immunodiagnostics |
| NZ703514A NZ703514A (en) | 2010-10-27 | 2011-10-27 | Fviii peptides for immune tolerance induction and immunodiagnostics |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ703514A NZ703514A (en) | 2010-10-27 | 2011-10-27 | Fviii peptides for immune tolerance induction and immunodiagnostics |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8969524B2 (enExample) |
| EP (2) | EP3260132B1 (enExample) |
| JP (2) | JP6122780B2 (enExample) |
| KR (2) | KR102040867B1 (enExample) |
| CN (2) | CN103298482B (enExample) |
| AR (1) | AR083586A1 (enExample) |
| AU (2) | AU2011319747C1 (enExample) |
| BR (1) | BR112013010362A2 (enExample) |
| CA (1) | CA2815239C (enExample) |
| DK (1) | DK2632479T3 (enExample) |
| EA (1) | EA034494B1 (enExample) |
| ES (2) | ES2912455T3 (enExample) |
| HK (1) | HK1215442A1 (enExample) |
| MX (1) | MX347805B (enExample) |
| NZ (2) | NZ609474A (enExample) |
| PL (2) | PL3260132T3 (enExample) |
| PT (1) | PT2632479T (enExample) |
| SG (2) | SG189914A1 (enExample) |
| TW (3) | TW201730205A (enExample) |
| WO (1) | WO2012058480A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006063031A2 (en) | 2004-12-06 | 2006-06-15 | Haplomics | Allelic variants of human factor viii |
| PL2917232T3 (pl) * | 2012-11-12 | 2017-09-29 | Apitope International Nv | Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A |
| US10272163B2 (en) | 2012-12-07 | 2019-04-30 | The Regents Of The University Of California | Factor VIII mutation repair and tolerance induction |
| EP2968499A4 (en) * | 2013-03-15 | 2016-11-30 | Haplomics Inc | COMPOSITIONS AND METHODS FOR THE IMMUNO-TOLERANCE INDUCTION FOR FACTOR VIII SPATIAL THERAPIES IN PERSONS WITH HEMOPHILIA A |
| WO2015192101A1 (en) * | 2014-06-12 | 2015-12-17 | University Of Hawaii | Uses of humanized cobra venom factor for reducing or preventing immunogenicity |
| CA2973529A1 (en) * | 2015-01-26 | 2016-08-04 | Cellectis | Cll1-specific multi-chain chimeric antigen receptor |
| SG11201808475XA (en) | 2016-04-15 | 2018-10-30 | Baxalta Inc | Method and apparatus for providing a pharmacokinetic drug dosing regiment |
| US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005538694A (ja) * | 2002-04-18 | 2005-12-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 修飾されたｖｉｉｉ因子 |
| US7485314B2 (en) * | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| WO2005114221A2 (en) * | 2004-05-21 | 2005-12-01 | The Institute For Systems Biology | Compositions and methods for quantification of serum glycoproteins |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| ES2474573T3 (es) | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
| GB0723712D0 (en) | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
| US7673687B2 (en) | 2007-12-05 | 2010-03-09 | Halliburton Energy Services, Inc. | Cement compositions comprising crystalline organic materials and methods of using same |
| DE202007017320U1 (de) | 2007-12-07 | 2008-02-28 | Dittmann, Ludwig | Vorrichtung zur Raumbeduftung |
| GB0801513D0 (en) * | 2008-01-28 | 2008-03-05 | Circassia Ltd | Peptides from factor VIII |
| US20110081362A1 (en) | 2008-01-31 | 2011-04-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| US20100168018A1 (en) | 2008-11-07 | 2010-07-01 | Baxter International Inc. | Factor viii formulations |
-
2011
- 2011-10-27 DK DK11796846.1T patent/DK2632479T3/en active
- 2011-10-27 NZ NZ609474A patent/NZ609474A/en unknown
- 2011-10-27 AU AU2011319747A patent/AU2011319747C1/en active Active
- 2011-10-27 EP EP17167928.5A patent/EP3260132B1/en active Active
- 2011-10-27 TW TW106113613A patent/TW201730205A/zh unknown
- 2011-10-27 WO PCT/US2011/058165 patent/WO2012058480A1/en not_active Ceased
- 2011-10-27 BR BR112013010362A patent/BR112013010362A2/pt not_active Application Discontinuation
- 2011-10-27 CN CN201180063117.9A patent/CN103298482B/zh active Active
- 2011-10-27 SG SG2013028733A patent/SG189914A1/en unknown
- 2011-10-27 EA EA201390617A patent/EA034494B1/ru not_active IP Right Cessation
- 2011-10-27 PL PL17167928.5T patent/PL3260132T3/pl unknown
- 2011-10-27 CA CA2815239A patent/CA2815239C/en active Active
- 2011-10-27 KR KR1020137013231A patent/KR102040867B1/ko active Active
- 2011-10-27 NZ NZ703514A patent/NZ703514A/en unknown
- 2011-10-27 CN CN201510431485.4A patent/CN104926947A/zh active Pending
- 2011-10-27 ES ES17167928T patent/ES2912455T3/es active Active
- 2011-10-27 JP JP2013536845A patent/JP6122780B2/ja active Active
- 2011-10-27 MX MX2013004753A patent/MX347805B/es active IP Right Grant
- 2011-10-27 TW TW105138248A patent/TW201708251A/zh unknown
- 2011-10-27 PL PL11796846T patent/PL2632479T3/pl unknown
- 2011-10-27 ES ES11796846.1T patent/ES2639039T3/es active Active
- 2011-10-27 PT PT117968461T patent/PT2632479T/pt unknown
- 2011-10-27 KR KR1020197032106A patent/KR102222864B1/ko not_active Expired - Fee Related
- 2011-10-27 US US13/283,452 patent/US8969524B2/en active Active
- 2011-10-27 EP EP11796846.1A patent/EP2632479B1/en active Active
- 2011-10-27 TW TW100139078A patent/TWI580430B/zh active
- 2011-10-27 SG SG10201600656WA patent/SG10201600656WA/en unknown
- 2011-10-28 AR ARP110103988A patent/AR083586A1/es not_active Application Discontinuation
-
2015
- 2015-01-23 US US14/604,622 patent/US9512198B2/en active Active
-
2016
- 2016-03-22 HK HK16103339.6A patent/HK1215442A1/zh unknown
- 2016-04-06 AU AU2016202155A patent/AU2016202155B2/en active Active
- 2016-11-02 US US15/341,936 patent/US20170267743A1/en not_active Abandoned
- 2016-11-29 JP JP2016230723A patent/JP2017095463A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ609474A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
| NZ602845A (en) | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| NZ602943A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| NZ628126A (en) | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases | |
| NZ707439A (en) | Modified factor ix polypeptides and uses thereof | |
| NZ609216A (en) | Anticancer fusion protein | |
| PH12012500849A1 (en) | Mycobacterial vaccines | |
| IN2014KN01713A (enExample) | ||
| IN2014KN01714A (enExample) | ||
| IN2014KN01716A (enExample) | ||
| NZ598356A (en) | Antigenic tau peptides and uses thereof | |
| NZ611176A (en) | Peptide scaffold design | |
| MX2015003310A (es) | Moleculas de union il-17a novedosas y usos medicos de las mismas. | |
| NZ601488A (en) | Immunogenic proteins and compositions | |
| IN2014DN09963A (enExample) | ||
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| MX394834B (es) | Proteína de fusión para usarse en el tratamiento/prevención de una infección por virus de hepatitis b. | |
| NZ591133A (en) | Novel melanoma antigen peptide and uses thereof | |
| WO2012031103A3 (en) | Inhibitors of bcl-2 | |
| EA201590431A1 (ru) | Пшеница с новыми аллелями rht-b1 | |
| PH12013502292A1 (en) | Protein f - a novel haemophilus influenzae adhesin with laminin and vitronectin binding properties | |
| GB201018125D0 (en) | Peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2016 BY COMPUTER PACKAGES INC Effective date: 20151031 |
|
| ASS | Change of ownership |
Owner name: BAXALTA INC, US Effective date: 20160414 Owner name: BAXALTA GMBH, CH Effective date: 20160414 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2017 BY COMPUTER PACKAGES INC Effective date: 20161001 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2018 BY ANAQUA SERVICES Effective date: 20170920 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2019 BY ANAQUA SERVICES Effective date: 20180919 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2020 BY ANAQUA SERVICES Effective date: 20190918 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2021 BY ANAQUA SERVICES Effective date: 20200917 |
|
| ASS | Change of ownership |
Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP Effective date: 20210330 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2022 BY ANAQUA SERVICES Effective date: 20210921 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2023 BY ANAQUA SERVICES Effective date: 20220922 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2024 BY ANAQUA SERVICES Effective date: 20230921 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2025 BY ANAQUA SERVICES Effective date: 20240920 |